{
  "id": 196554,
  "name": "GENENTECH",
  "slug": "genentech",
  "state": "CA",
  "description": "A biotechnology corporation",
  "totalSpending": 1550000,
  "filings": 27,
  "yearlySpending": [
    {
      "year": 2018,
      "income": 200000
    },
    {
      "year": 2019,
      "income": 150000
    },
    {
      "year": 2020,
      "income": 200000
    },
    {
      "year": 2021,
      "income": 150000
    },
    {
      "year": 2022,
      "income": 150000
    },
    {
      "year": 2023,
      "income": 200000
    },
    {
      "year": 2024,
      "income": 150000
    },
    {
      "year": 2025,
      "income": 150000
    }
  ],
  "firms": [
    "FORBES-TATE"
  ],
  "lobbyists": [
    "JEFFREY FORBES",
    "JERRY DRISCOLL",
    "ELIZABETH GREER",
    "DERRICK WHITE",
    "ZACHARY WILLIAMS",
    "CYNTHIA BROWN",
    "BARRETT THORNHILL",
    "FRANCESCA MCCRARY",
    "MICHAEL WILLIAMS",
    "KRISTINA DUNKLIN"
  ],
  "issues": [
    "MMM",
    "TAX",
    "CPT",
    "MED",
    "MAN",
    "BUD",
    null,
    "HCR"
  ],
  "sampleDescriptions": [
    "Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug reimportation; Issues related to RX drug pricing.",
    "Tax related issues.",
    "Intellectual property and process patent issues.",
    "Issues related to Right to Try.",
    "Issues related to Right to Try; Issues related to Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018, S. 2852.",
    "Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug reimportation; Issues related to RX drug pricing; Issues related to the International Pricing Index for Medicare Part D.",
    "Intellectual property and process patent Issues.",
    "Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to RX drug pricing; Issues related to the International Pricing Index for Medicare Part D.",
    "Intellectual property and process patent related issues.",
    "Issues related to the Capability Maturity Model Integration (CMMI).",
    "Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D.",
    "Issues related to H.R. 925 - The Heroes Act.",
    "Issues regarding the Center for Medicare and Medicaid Innovation.",
    "Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260).",
    "Issues related to internal tax and R&D amortization credit in the H.R.5376 - Build Back Better Act; Issues related to tax.",
    "Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D; Issues related to prescription drug user fee agreement; Issues related to H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).",
    "Issues related to internal tax and R&D amortization credit in the H.R.5376 - Build Back Better Act; Issues related to tax; Issues related to H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).",
    "Issues regarding the Center for Medicare and Medicaid Innovation; Issues related to H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).",
    "Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260); Issues related to funding of the strategic national stockpile; Issues related to H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).",
    "Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D; Issues related to prescription drug user fee agreement; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program."
  ],
  "years": [
    2018,
    2019,
    2020,
    2021,
    2022,
    2023,
    2024,
    2025
  ],
  "growthRate": -25,
  "trajectory": "reducing",
  "yearsActive": 8,
  "avgAnnualSpending": 168750,
  "peakYear": 2018,
  "lobbyistCount": 10,
  "firmCount": 1,
  "issueCount": 7,
  "industry": "technology"
}